Technology
Health
Pharmaceutical

Zymeworks

$17.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.23%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!

About

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Employees
183
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
565.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
143.30K
High Today
$18.17
Low Today
$17.57
Open Price
$17.97
Volume
17.78K
52 Week High
$29.00
52 Week Low
$10.72

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2017 IPO
Canada
North America

News

Financial PostMay 23

Zymeworks Announces Corporate Update Conference Call

VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships. Zymeworks will host a webcast and conference call on Wednesday, May 29, 2019 at 8:30am ET (5:30am PT...

1
Seeking AlphaMay 16

GSK expands collaboration with Zymeworks

GlaxoSmithKline (NYSE:GSK) has expanded the scope of its 2016 licensing and collaboration partnership with Zymeworks (NYSE:ZYME), now enabling access to the latter's heavy-light chain pairing technology which is part of its Azymetric platform.

33
Yahoo FinanceMay 9

Is Zymeworks Inc. A Good Stock To Buy?

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.

24

Earnings

-$0.83
-$0.13
$0.58
$1.28
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.